• Consensus Rating: Reduce
  • Consensus Price Target: $19.40
  • Forecasted Upside: 111.56%
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 10 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.17
▲ +0.36 (4.09%)

This chart shows the closing price for NVRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nevro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVRO

Analyst Price Target is $19.40
▲ +111.56% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $19.40, with a high forecast of $40.00 and a low forecast of $8.20. The average price target represents a 111.56% upside from the last price of $9.17.

This chart shows the closing price for NVRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 13 polled investment analysts is to reduce stock in Nevro. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
4/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
6/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings
7/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 10 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/10/2024CitigroupLower TargetSell ➝ Sell$9.00 ➝ $8.20Low
5/22/2024CitigroupDowngradeNeutral ➝ Sell$13.50 ➝ $9.00Low
5/8/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$17.00 ➝ $11.00Low
5/8/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00Low
5/8/2024Piper SandlerLower TargetUnderweight ➝ Underweight$15.00 ➝ $12.00Low
4/15/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00Low
4/11/2024MizuhoLower TargetNeutral ➝ Neutral$20.00 ➝ $16.00Low
4/8/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00Low
4/3/2024CitigroupLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00Low
2/22/2024Robert W. BairdLower TargetNeutral ➝ Neutral$23.00 ➝ $19.00Low
2/22/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$20.00 ➝ $17.00Low
2/22/2024OppenheimerDowngradeOutperform ➝ Market PerformLow
1/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$23.00 ➝ $20.00Low
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$22.00 ➝ $23.00Low
12/21/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$23.00Low
12/21/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$23.00Low
12/1/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$23.00Low
11/3/2023Truist FinancialLower TargetHold ➝ Hold$18.50 ➝ $17.00Low
11/2/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$23.00 ➝ $18.00N/A
11/2/2023Piper SandlerLower TargetUnderweight ➝ Underweight$24.00 ➝ $15.00N/A
11/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$23.00 ➝ $18.00Low
8/21/2023CitigroupLower TargetNeutral ➝ Neutral$24.00 ➝ $21.00Low
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$33.00Low
8/3/2023Truist FinancialLower TargetHold ➝ Hold$27.00 ➝ $25.00Low
8/2/2023OppenheimerLower TargetOutperform ➝ Outperform$40.00 ➝ $35.00Low
8/2/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$27.00 ➝ $23.00Low
8/2/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$29.00 ➝ $23.00N/A
8/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$28.00 ➝ $23.00N/A
8/2/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$68.00 ➝ $57.00Low
8/2/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$39.00 ➝ $33.00Low
8/2/2023Robert W. BairdLower TargetNeutral ➝ Neutral$26.00 ➝ $23.00Low
8/2/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$75.00 ➝ $40.00Low
7/19/2023Truist FinancialLower TargetHold$30.00 ➝ $27.00Low
7/18/2023Robert W. BairdInitiated CoverageNeutral$26.00Low
7/17/2023MizuhoLower Target$40.00 ➝ $30.00Low
6/28/2023JPMorgan Chase & Co.Lower Target$40.00 ➝ $28.00Low
6/7/2023CitigroupLower Target$37.00 ➝ $27.00Low
6/6/2023Truist FinancialLower Target$32.00 ➝ $30.00Low
5/31/2023Royal Bank of CanadaInitiated CoverageOutperform$40.00Low
5/18/2023Truist FinancialLower Target$40.00 ➝ $32.00Low
5/15/2023OppenheimerUpgradeMarket Perform ➝ Outperform$40.00Low
4/27/2023Piper SandlerLower Target$37.00 ➝ $34.00Low
4/17/2023Truist FinancialLower TargetHold$42.00 ➝ $40.00Low
4/13/2023MizuhoInitiated CoverageNeutral$40.00Low
2/6/2023Canaccord Genuity GroupBoost TargetBuy$67.00 ➝ $72.00Low
1/26/2023Piper SandlerLower TargetUnderweight$38.00 ➝ $37.00Low
1/17/2023CitigroupDowngradeBuy ➝ Neutral$40.00Low
1/11/2023Wells Fargo & CompanyLower TargetEqual Weight$43.00 ➝ $37.00Low
1/6/2023Morgan StanleyLower TargetEqual Weight$49.00 ➝ $46.00Low
1/6/2023Piper SandlerDowngradeNeutral ➝ Underweight$42.00 ➝ $38.00N/A
12/20/2022Truist FinancialLower TargetHold$45.00 ➝ $41.00Low
12/20/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$41.00 ➝ $67.00Low
12/12/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$66.00 ➝ $43.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetNeutral$50.00 ➝ $40.00Low
11/3/2022Piper SandlerLower TargetNeutral$45.00 ➝ $42.00Low
11/2/2022William BlairReiterated RatingMarket PerformLow
10/12/2022Jefferies Financial GroupInitiated CoverageUnderperform$31.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$54.00 ➝ $49.00Low
8/4/2022Morgan StanleyLower TargetEqual Weight$55.00 ➝ $54.00N/A
8/4/2022Wells Fargo & CompanyLower TargetOverweight$90.00 ➝ $86.00Low
8/4/2022Piper SandlerLower TargetNeutral$64.00 ➝ $45.00Low
7/22/2022Truist FinancialLower Target$45.00Low
6/7/2022Morgan StanleyLower TargetEqual Weight$74.00 ➝ $55.00Low
5/26/2022JMP SecuritiesLower TargetMarket Outperform$125.00 ➝ $95.00Low
5/17/2022CitigroupLower Target$78.00 ➝ $68.00N/A
5/5/2022CitigroupUpgradeNeutral ➝ Buy$78.00High
5/5/2022Piper SandlerLower Target$65.00 ➝ $64.00High
4/5/2022Wolfe ResearchInitiated CoverageUnderperform$64.00High
3/2/2022Bank of AmericaInitiated CoverageUnderperform ➝ UnderperformHigh
2/25/2022Morgan StanleyLower TargetEqual Weight$100.00 ➝ $76.00High
2/25/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$97.00 ➝ $72.00High
2/24/2022SVB LeerinkLower TargetOutperform$105.00 ➝ $85.00High
2/24/2022Wells Fargo & CompanyLower TargetOverweight$116.00 ➝ $90.00High
2/24/2022Piper SandlerLower TargetNeutral$92.00 ➝ $65.00High
1/12/2022Canaccord Genuity GroupLower TargetHold ➝ Hold$118.00 ➝ $97.00Low
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$140.00 ➝ $100.00High
1/3/2022Piper SandlerLower Target$115.00 ➝ $90.00High
12/21/2021Truist FinancialLower TargetHold$105.00 ➝ $95.00High
12/6/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$116.00High
11/19/2021SVB LeerinkReiterated RatingBuy$128.00High
11/9/2021Truist FinancialDowngradeBuy ➝ Hold$165.00 ➝ $105.00High
11/9/2021Wells Fargo & CompanyLower TargetEqual Weight$122.00 ➝ $116.00High
11/9/2021CitigroupLower TargetNeutral$125.00 ➝ $120.00High
11/9/2021Piper SandlerLower TargetIn-Line ➝ Neutral$125.00 ➝ $115.00High
11/9/2021SVB LeerinkLower TargetOutperform$147.00 ➝ $128.00High
8/5/2021Truist FinancialLower TargetPositive ➝ Buy$205.00 ➝ $165.00High
8/5/2021Morgan StanleyLower TargetOverweight$199.00 ➝ $150.00High
8/5/2021SVB LeerinkLower TargetOutperform$210.00 ➝ $147.00High
8/5/2021JMP SecuritiesLower TargetOutperform$190.00 ➝ $160.00High
8/5/2021William BlairDowngradeOutperform ➝ Market PerformHigh
8/5/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$122.00High
8/5/2021CitigroupDowngradeBuy ➝ Neutral$198.00 ➝ $125.00High
8/5/2021Piper SandlerDowngradeOverweight ➝ Neutral$200.00 ➝ $125.00High
7/9/2021Redburn PartnersDowngradeBuy ➝ NeutralLow
7/6/2021Robert W. BairdDowngradeOutperform ➝ Neutral$188.00 ➝ $150.00High
7/2/2021SVB LeerinkReiterated RatingBuyMedium
6/28/2021Wells Fargo & CompanyLower TargetOverweight$215.00 ➝ $202.00Medium
6/28/2021Robert W. BairdLower TargetOutperform$200.00 ➝ $188.00High
6/28/2021Piper SandlerBoost TargetOverweight$190.00 ➝ $200.00High
3/4/2021SVB LeerinkReiterated RatingBuyHigh
2/26/2021Morgan StanleyBoost TargetOverweight$192.00 ➝ $199.00Low
2/2/2021Piper SandlerInitiated CoverageOverweight$190.00N/A
1/19/2021SVB LeerinkBoost TargetPositive ➝ Outperform$190.00 ➝ $210.00Medium
1/6/2021Truist FinancialBoost Target$175.00 ➝ $205.00N/A
1/5/2021Robert W. BairdBoost TargetOutperform$180.00 ➝ $200.00N/A
1/4/2021Wells Fargo & CompanyBoost TargetOverweight$177.00 ➝ $215.00N/A
12/31/2020GuggenheimBoost TargetBuy$190.00 ➝ $205.00N/A
12/15/2020Morgan StanleyBoost TargetOverweight$161.00 ➝ $192.00Medium
11/11/2020JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $190.00Low
11/6/2020Morgan StanleyBoost TargetOverweight$150.00 ➝ $161.00Low
10/22/2020GuggenheimInitiated CoverageBuy$190.00Low
10/21/2020OTR GlobalUpgradePositiveLow
10/12/2020SVB LeerinkBoost TargetOutperform$165.00 ➝ $175.00Low
9/1/2020Robert W. BairdInitiated CoverageOutperform$160.00Low
8/6/2020Morgan StanleyBoost TargetOverweight$145.00 ➝ $150.00Medium
8/6/2020Wells Fargo & CompanyBoost TargetOverweight$141.00 ➝ $153.00High
8/6/2020SVB LeerinkBoost TargetOutperform$140.00 ➝ $165.00High
8/6/2020CitigroupBoost TargetBuy$137.00 ➝ $160.00High
8/5/2020OppenheimerInitiated CoverageHoldHigh
6/18/2020Morgan StanleyBoost Target$135.00 ➝ $145.00High
6/18/2020CitigroupBoost TargetOverweight$135.00 ➝ $145.00High
6/8/2020UBS GroupUpgradeSell ➝ Neutral$100.00 ➝ $132.00High
6/4/2020SunTrust BanksReiterated RatingBuy$135.00High
5/6/2020SunTrust BanksBoost TargetBuy$120.00 ➝ $135.00Medium
5/6/2020Morgan StanleyBoost TargetOverweight$113.00 ➝ $135.00Medium
5/6/2020JPMorgan Chase & Co.Boost TargetNeutral$90.00 ➝ $100.00Low
5/6/2020CitigroupBoost TargetBuy$130.00 ➝ $137.00Low
4/3/2020Morgan StanleyLower TargetOverweight$118.00 ➝ $113.00Low
4/2/2020JPMorgan Chase & Co.Lower TargetNeutral$130.00 ➝ $90.00High
4/2/2020SunTrust BanksLower TargetBuy$146.00 ➝ $120.00High
4/2/2020Wells Fargo & CompanyLower TargetOverweight$158.00 ➝ $126.00High
3/27/2020Morgan StanleyLower TargetOverweight$142.00 ➝ $118.00Low
3/27/2020CitigroupLower TargetBuy$160.00 ➝ $130.00High
3/4/2020CitigroupInitiated CoverageBuy$160.00Low
2/26/2020SVB LeerinkBoost TargetOutperform ➝ Positive$146.00 ➝ $158.00High
2/26/2020Wells Fargo & CompanyBoost TargetOverweight$144.00 ➝ $158.00High
2/26/2020JPMorgan Chase & Co.Boost TargetNeutral$96.00 ➝ $130.00High
1/27/2020Morgan StanleyBoost TargetOverweight$125.00 ➝ $142.00High
1/27/2020JMP SecuritiesBoost TargetOutperform$115.00 ➝ $150.00High
1/21/2020Wells Fargo & CompanyBoost TargetOverweight$135.00 ➝ $144.00Low
1/15/2020UBS GroupBoost TargetSell$77.00 ➝ $84.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$132.00Low
1/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
12/20/2019JPMorgan Chase & Co.Boost TargetNeutral$80.00 ➝ $96.00Low
12/17/2019Morgan StanleyBoost TargetOverweight$100.00 ➝ $125.00Low
11/7/2019OppenheimerUpgradeMarket Perform ➝ Outperform$106.00High
11/7/2019Wells Fargo & CompanyBoost TargetOutperform$86.00 ➝ $105.00High
11/7/2019JMP SecuritiesBoost TargetOutperform$115.00High
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
10/9/2019Wells Fargo & CompanyBoost TargetOutperform$70.00 ➝ $86.00Low
8/23/2019SVB LeerinkSet TargetBuy$98.00Medium
8/12/2019JMP SecuritiesBoost TargetMarket Outperform$70.00 ➝ $90.00High
8/9/2019Morgan StanleySet TargetBuy$76.00Medium
8/9/2019Northland SecuritiesSet TargetHold$65.00Medium
8/9/2019Bank of AmericaBoost TargetBuy$70.00 ➝ $74.00N/A
(Data available from 7/15/2019 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/18/2023
  • 1 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
1/17/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/16/2024
  • 6 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/17/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/16/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/16/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/15/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Nevro logo
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $9.17
Low: $8.96
High: $9.40

50 Day Range

MA: $9.30
Low: $7.61
High: $11.53

52 Week Range

Now: $9.17
Low: $7.46
High: $25.45

Volume

589,800 shs

Average Volume

527,370 shs

Market Capitalization

$336.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?

The following Wall Street research analysts have issued stock ratings on Nevro in the last year: Canaccord Genuity Group Inc., Citigroup Inc., JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for NVRO.

What is the current price target for Nevro?

13 Wall Street analysts have set twelve-month price targets for Nevro in the last year. Their average twelve-month price target is $19.40, suggesting a possible upside of 111.6%. JMP Securities has the highest price target set, predicting NVRO will reach $40.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $8.20 for Nevro in the next year.
View the latest price targets for NVRO.

What is the current consensus analyst rating for Nevro?

Nevro currently has 2 sell ratings, 10 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for NVRO.

What other companies compete with Nevro?

How do I contact Nevro's investor relations team?

Nevro's physical mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider's listed phone number is (650) 251-0005 and its investor relations email address is [email protected]. The official website for Nevro is www.nevro.com. Learn More about contacing Nevro investor relations.